Clinical Application of Lobaplatin Combined with Docetaxel in Adjuvant Chemotherapy for Triple-Negative Breast Cancer in Elderly Patients

To investigate the adverse reactions and efficacy of docetaxel combined with lobaplatin in adjuvant chemotherapy for triple-negative breast cancer in elderly patients.A total of 96 elderly triple-negative breast cancer patients admitted to our hospital from January 2008 to December 2011 were randomly divided into two groups.A group of 56 patients received docetaxel 75 mg·m^(-2),intravenous drip,d1;lobaplatin 30 mg·m^(-2),intravenous drip,d1;21 days repeat,a total of 6 cycles.A group of 40 patients received chemotherapy for 6 cycles with an anthracycline-containing(TEC)regimen.Comparison of adverse reactions and 5-year diseasefree survival in both groups.The incidence of thrombocytopenia was significantly higher in 56 patients with TL regimen than those with TCE-containing anthracyclines(P=0.005).But the incidence of cardiotoxicity was 32.5%in the TEC group.And the difference was statistically significant(P=0.008).The 5-year disease-free survival rate was 73.2%in the TL group and 67.5%in the TEC group.There was no statistical difference.Docetaxel combined with lobaplatin in the treatment of elderly triple-negative breast cancer has no significant difference in efficacy compared with traditional anthracycline-containing drugs,but it can avoid the cardiotoxicity caused by anthracyclines.It’s a new option for elderly TNBC adjuvant chemotherapy,suggesting to expand the sample content for further research.

Unrestricted molecular motions enable mild photothermy for recurrence-resistant FLASH antitumor radiotherapy

Ultrahigh dose-rate(FLASH)radiotherapy is an emerging technology with excellent therapeutic effects and low biological toxicity.However,tumor recurrence largely impede the effectiveness of FLASH therapy.Overcoming tumor recurrence is crucial for practical FLASH applications.Here,we prepared an agarose-based thermosensitive hydrogel containing a mild photothermal agent(TPE-BBT)and a glutaminase inhibitor(CB-839).Within nanoparticles,TPE-BBT exhibits aggregation-induced emission peaked at 900 nm,while the unrestricted molecular motions endow TPE-BBT with a mild photothermy generation ability.The balanced photothermal effect and photoluminescence are ideal for phototheranostics.Upon 660-nm laser irradiation,the temperature-rising effect softens and hydrolyzes the hydrogel to release TPE-BBT and CB-839 into the tumor site for concurrent mild photothermal therapy and chemotherapy,jointly inhibiting homologous recombination repair of DNA.The enhanced FLASH radiotherapy efficiently kills the tumor tissue without recurrence and obvious systematic toxicity.This work deciphers the unrestricted molecular motions in bright organic fluorophores as a source of photothermy,and provides novel recurrence-resistant radiotherapy without adverse side effects.